Plasma cell myeloma

This trial is testing an experimental therapy called CT0596, which uses a patient's own immune cells that are engineered to recognize and attack multiple myeloma cells. The study includes adults with relapsed or refractory multiple myeloma who have already tried at least three pr…

This phase 1 trial tests VV169, a therapy that aims to create CAR-T cells inside the body to fight multiple myeloma. Researchers give VV169 as an infusion to adults whose cancer has returned or stopped responding to at least three prior treatments. The study focuses on safety, fi…

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

This Phase III trial is testing whether a single infusion of AZD0120, a CAR-T therapy that targets two proteins on myeloma cells, can keep the cancer at bay better than continuous standard treatment. It enrolls adults newly diagnosed with multiple myeloma who are not eligible for…

This study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This study tests whether adding low-dose radiation to the drug elranatamab can better kill cancer cells in people with multiple myeloma that has come back or not responded to treatment and has spread outside the bone. About 34 adults will receive the combination. The goal is to s…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and maraviroc) can safely prevent graft-versus-host disease after a half-matched bone marrow transplant in people living with HIV who also have a blood cancer. The trial involves 265 participants…

This study tests a new antibody drug called HuL001, given together with two standard myeloma drugs (lenalidomide and dexamethasone), in 21 adults whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see if the combination is safe and can s…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…

This study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This early-phase trial is testing an experimental antibody called cevostamab, either alone or combined with other drugs (pomalidomide, daratumumab, and dexamethasone), in 126 people with multiple myeloma that has returned or stopped responding to treatment. The main goals are to …

This Phase 3 trial tests a new drug called IBI3003 against standard treatments for people with multiple myeloma that has returned or is not responding to therapy. About 255 participants will be randomly assigned to receive either IBI3003 or a standard treatment chosen by their do…

This study tests an experimental drug, HDP-101, in people with multiple myeloma or related plasma cell disorders. The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments, including stem cell transplant or are not eligible for…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This phase 2 trial is testing a combination of two drugs—CM336 (a bispecific antibody) and isatuximab (a monoclonal antibody)—in 20 people newly diagnosed with multiple myeloma who also have severe kidney impairment. The goal is to see if the treatment can improve kidney function…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

Researchers are testing whether adding cevostamab to pomalidomide and dexamethasone helps people with multiple myeloma whose cancer returned after BCMA CAR-T therapy. The trial enrolls about 45 adults who have had one to four prior treatments, including a BCMA CAR-T therapy and s…

This study is testing whether people with multiple myeloma that has come back or stopped responding to other treatments can safely take a lower dose of the drug linvoseltamab once their cancer starts to improve. Linvoseltamab works by helping the body's immune cells find and kill…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study tests two drugs, elranatamab and isatuximab, given as shots under the skin for people with multiple myeloma that has returned or not responded to at least two prior treatments. The goal is to see if the combination can shrink tumors and control the disease. About 30 pa…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This phase 3 trial compares an experimental drug, linvoseltamab, to an existing drug, daratumumab, in 270 people with smoldering multiple myeloma at high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the disease longer. Participants wil…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This phase II trial compares a new combination of daratumumab and teclistamab against standard treatments for high-risk multiple myeloma that has relapsed or not responded to therapy. About 80 adults will be randomly assigned to either the new combo or usual care. The goal is to …

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This early-stage trial is testing a new treatment called KSVCBD for people with multiple myeloma that has come back or not responded to at least three prior treatments. KSVCBD is a type of CAR-T cell therapy given directly into the body to target two proteins (CD19 and BCMA) on m…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This phase 3 trial is testing a new CAR-T cell therapy called arlo-cel against standard treatments for adults with multiple myeloma that has come back or stopped responding to previous therapies. About 440 participants will receive either arlo-cel or a standard regimen. The study…

This study is for older adults with newly diagnosed multiple myeloma who cannot have a stem cell transplant. It compares taking the drugs daratumumab or isatuximab continuously versus stopping after about a year and a half, while continuing other medications. The goal is to see i…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests whether IgPro20 (HIZENTRA), a concentrated antibody solution given under the skin, can prevent infections in people with multiple myeloma who have low antibody levels due to bispecific antibody therapy. About 100 participants will either receive IgPro20 plus stan…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This early-phase trial is testing a new oral drug called BG-75202, alone or with another medicine, in about 118 adults with myeloid blood cancers that have come back or not responded to prior treatment. The main goals are to check safety, find the right dose, and get a first look…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This study tests a new treatment called arlocabtagene autoleucel (BMS-986393) for adults with multiple myeloma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The study aims to see if this tr…

This study tests whether adding motixafortide to standard G-CSF helps collect more stem cells for a bone marrow transplant in people with multiple myeloma. About 60 Chinese adults with active myeloma will receive either the drug combo or a placebo before stem cell collection. The…

This study is testing an experimental drug called surzetoclax, alone or combined with other cancer drugs, in about 130 adults with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and see if it can shrink or control…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This study tests whether a non-invasive ventilation mask (NIPPV) can reduce the need for intubation in cancer patients with respiratory failure. Researchers will compare NIPPV plus standard oxygen therapy to standard oxygen therapy alone in 256 participants. The goal is to see if…

This study tests a drug called talquetamab in elderly patients whose multiple myeloma has come back after earlier treatments. The drug helps the body's immune cells attack the cancer. If the drug stops working, another drug called daratumumab may be added. The goal is to see if t…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This study tests a new drug called sonrotoclax, alone or with other medicines, in people with a type of multiple myeloma that has come back or stopped responding to treatment. The trial includes 246 participants and aims to find the safest and most effective dose. Researchers wil…

This study tests a new drug, linvoseltamab, alone or with another drug called carfilzomib, against standard treatments for people with multiple myeloma that has returned or not responded to prior therapy. About 915 participants who have had 1 to 3 prior treatments will be enrolle…

This early-phase trial is testing a combination of two drugs—teclistamab and iberdomide—in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to find the safest and most effective dose of iberdomide when used with teclistamab. About 26…

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This study tests whether adding daratumumab to standard treatment (bortezomib and dexamethasone) can improve kidney function better than the usual approach (cyclophosphamide, bortezomib, and dexamethasone) in people newly diagnosed with multiple myeloma who also have kidney failu…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-phase study tests a new drug called RO7851624 in 160 people with relapsed/refractory multiple myeloma who have tried several standard treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the dr…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…

This study tests a new way to do stem cell transplants for adults with high-risk blood cancers who don't have a fully matched donor. Doctors will use stem cells from a half-matched (haploidentical) donor and remove certain immune cells to try to prevent severe graft-versus-host d…

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-phase study tests a new experimental drug, REGN17372, combined with another drug called linvoseltamab in people with relapsed or refractory multiple myeloma (cancer that has returned or stopped responding to treatment). The main goals are to check safety, find the best…

This study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma. The 30 participants have already tried at least four prior treatments. Researchers will…

This study tests an experimental drug called LBL-034 in people whose multiple myeloma has returned or no longer responds to standard treatments. The trial has two phases: first, finding the safest dose, and then checking how well the drug shrinks tumors. About 342 adults will tak…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This phase 2 trial tests a gradual, three-drug combination (isatuximab, dexamethasone, and lenalidomide) in 40 ultra-frail patients newly diagnosed with multiple myeloma. The goal is to see if starting treatment slowly improves how well patients tolerate therapy and their quality…

This study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults whose cancer came back after 1 to 3 prior therapies will take part. The goal is to…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This early-phase study tests a new drug called HRS-3005 in 190 adults with B-cell blood cancers (like lymphoma or leukemia) that have returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and get a first look at wheth…

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This Phase 3 trial is testing whether a new drug called mezigdomide, combined with two standard drugs (bortezomib and dexamethasone), works better than the current standard combination (pomalidomide, bortezomib, and dexamethasone) for people with multiple myeloma that has come ba…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This Phase 3 trial tests whether giving immune globulin (IGI) regularly can prevent serious infections in adults with multiple myeloma who are receiving a bispecific antibody therapy. About 183 participants will be randomly assigned to get IGI right away for 12 months or only aft…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This study tests whether the drug elranatamab can be given safely in an outpatient clinic instead of the hospital for people with multiple myeloma that has come back or stopped responding to treatment. About 46 adults will receive the drug along with a single preventive dose of a…

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This early-stage study tests a new drug, PF-07994525, in about 120 adults with advanced multiple myeloma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. The study has two parts:…

This trial tests an experimental drug called FH-006 in 150 people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if FH-006 is safe, tolerable, and can shrink tumors. Researchers will measure how the drug moves through the body and …

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This early-phase trial is testing an experimental drug called CT7439, taken as a capsule, in about 50 people with solid tumors that have spread or cannot be removed. The study will first test CT7439 alone, then in combination with other cancer treatments. The main goals are to ch…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This phase 2 trial is testing whether a combination of belantamab mafodotin, pomalidomide, and dexamethasone can help prevent high-risk myeloma from returning after a stem cell transplant. About 34 patients who have already responded to transplant will receive the drug combo as m…

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This early-stage trial is testing whether combining two drugs, cevostamab and elranatamab, is safe and tolerable for people with multiple myeloma that has returned or not responded to prior treatments. About 120 participants will receive the drugs, and researchers will monitor si…

This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…

This study tests whether adding the drug selinexor to standard bispecific antibody therapy can help people with relapsed or refractory multiple myeloma achieve deeper remissions. About 27 adults who have already tried at least 4 prior treatments will take selinexor alongside thei…

This study is testing several new drug combinations for people with multiple myeloma, a type of blood cancer. The trial is open to 200 participants who have already had some treatment. The goal is to see if these combinations are safe and help control the disease. Because multipl…

This study tests a new drug called SLS009, alone or with other medicines, in people with blood cancers like leukemia and lymphoma that have come back or not responded to treatment. It also includes newly diagnosed patients with high-risk leukemia. The goal is to see if the drug i…

This early-phase trial is testing a new treatment called IMV102 for people with relapsed/refractory multiple myeloma, a type of blood cancer that has not responded to at least three prior therapies. IMV102 is a personalized therapy made from the patient's own immune cells (CAR-T …

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests two drugs, mezigdomide and elranatamab, together in people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 62 adults will take part in this…

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This study tests a new treatment called AZD0120, which uses a patient's own immune cells engineered to attack two targets (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has returned or stopped responding to prior treatments. The study compares AZD0120 t…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This phase 2 study tests whether the drug elranatamab can lower the chance of multiple myeloma worsening after treatment with idecabtagene vicleucel (a CAR-T cell therapy). The study will enroll 32 adults with relapsed or refractory multiple myeloma. Participants will receive elr…

This phase 3 trial tests whether the drug triptorelin can protect the ovaries of adolescents and young adults with cancer who are receiving chemotherapy. Chemotherapy can damage the ovaries, making it hard or impossible to get pregnant later. Triptorelin temporarily pauses ovaria…

This study tests a combination of four drugs—iberdomide, bortezomib, dexamethasone, and isatuximab—for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this treatment can shrink or eliminate the cancer. About 75 p…

This early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…

This study tests a drug called CTO1681 in 54 adults with diffuse large B-cell lymphoma who are about to receive CAR-T therapy. The drug is taken three times daily for 15 days to prevent or reduce cytokine release syndrome, a potentially severe immune reaction. Researchers will mo…

This study tests whether starting tube feeding right after a stem cell transplant can reduce severe gut graft-versus-host disease (GVHD) in people with blood cancers or disorders. About 112 participants will be randomly assigned to either standard care or early tube feeding. The …

This study tests a combination of four drugs—selinexor, carfilzomib, isatuximab, and dexamethasone—in people whose multiple myeloma has come back or stopped responding to treatment. The trial has two parts: first, a small safety run-in to find the right dose, then a larger group …

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study tests whether giving a single dose of tocilizumab before the cancer drug ramantamig can prevent or reduce cytokine release syndrome (CRS), a serious flu-like reaction. About 230 adults with relapsed or refractory multiple myeloma will participate. Half will get tociliz…

This phase 3 study compares a new injectable drug, JNJ-79635322, to an existing one, teclistamab, in about 700 people with multiple myeloma that has returned after 1 to 3 prior treatments. The goal is to see which drug works better at shrinking tumors and delaying disease progres…

This phase 1 trial tests an experimental therapy called MDC-CAR-BCMA001 in adults with relapsed or refractory B-cell cancers, including multiple myeloma and diffuse large B-cell lymphoma. The treatment uses a patient's own immune cells, modified to target a protein called BCMA on…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This phase 3 trial is testing whether adding an experimental drug called inobrodib to a standard two-drug regimen (pomalidomide and dexamethasone) can help people whose multiple myeloma has come back or stopped responding to prior treatments. Participants will be randomly assigne…

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …

This pilot study tests whether drinking tea made from soursop leaves can reduce the number of cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) — blood cancers that have not responded to standard treatments. About 20 particip…

This phase 2 trial is testing whether linvoseltamab, an investigational biologic given by infusion, can turn minimal residual disease (MRD) from positive to negative in people with newly diagnosed multiple myeloma. Participants have already received initial combination therapy bu…

This study tests a new treatment called AZD0120 for people with multiple myeloma that has come back or stopped responding to at least three prior therapies. AZD0120 is a personalized cell therapy that reprograms a patient's own immune cells to attack two targets on myeloma cells …

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study tests whether a combination of two drugs (elranatamab and lenalidomide) can replace high-dose chemotherapy and stem cell transplant for people newly diagnosed with multiple myeloma. About 824 adults under 70 will be randomly assigned to either standard treatment or the…

This trial tests a personalized approach to treating advanced solid tumors. Doctors take a patient's own immune cells, train them to recognize that patient's specific cancer mutations, and inject them back under the skin. The goal is to see if these customized cells can safely tr…

This study tests a new experimental drug, REGN7945, combined with another experimental drug, linvoseltamab, in people with multiple myeloma that has returned or not responded to at least three prior treatments. The goal is to see if the combination is safe and can shrink tumors b…

This phase III trial is investigating whether adding an experimental drug called BCD-248 to daratumumab can improve outcomes for people with multiple myeloma that has returned or become resistant to treatment. The study will compare this new combination against the current standa…

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This phase 3 trial is for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. After six months of standard treatment with daratumumab, lenalidomide, and dexamethasone, participants are assigned to different immunotherapy combination…

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…

This trial tests a 16-week rehabilitation program called YATAC, designed specifically for young adults aged 18–39 who have or have had cancer. The program includes physical activity, mental health support, nutrition advice, and help with education or work. Researchers want to see…

This study tests whether a closely supervised resistance training program can improve functional mobility, body composition, and strength in people who have been treated for cancer. Participants aged 20 to 89 will follow a structured exercise regimen during or after their cancer …

This study tests whether adding a precise local treatment—like focused radiation or ablation—can help people whose cancer has a few new or growing spots while on standard therapy. Participants continue their usual medication while the resistant tumors are treated directly. The go…

This study is observing 50 patients with relapsed or refractory multiple myeloma who are taking melflufen plus dexamethasone as a later-line treatment. The goal is to see how well the drug controls the disease in routine medical practice, outside of a controlled trial. Researcher…

This phase 2 trial tests whether a combination of iberdomide (a pill) and daratumumab (an injection) can eliminate leftover cancer cells in multiple myeloma patients who still have minimal residual disease after a stem cell transplant. About 60 participants will receive up to 26 …

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This Phase 3 trial tests three different drug combinations for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. The goal is to see which combination leads to the deepest remission (measured by minimal residual disease negativity) after 18 …

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This study tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd)—in people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see how well the regimen controls the disease and what si…

This study tests a program called PASCA that helps doctors detect and manage complications like high blood pressure, kidney failure, chronic pain, and fatigue in multiple myeloma patients after a stem cell transplant. About 204 adults aged 18 to 70 will be randomly assigned to ei…

This early-phase trial tests whether stem cell transplants from donors whose tissue type does not fully match the patient can be safe and effective for people with blood cancers who have no other donor options. About 29 adults aged 18-60 will receive chemotherapy followed by the …

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This early-stage trial tests a new type of immunotherapy called CAR T-cells, which are made from a patient's own immune cells and engineered to recognize and attack a protein called KMA on myeloma cells. The study will enroll 12 adults with relapsed or refractory multiple myeloma…

This study tests a combination of two drugs, belantamab mafodotin and venetoclax, with or without dexamethasone, in people whose multiple myeloma has come back and is hard to treat. The cancer must have a specific genetic change called t(11;14). The goal is to find the safest dos…

This Phase 2 trial tests whether two bispecific antibody drugs, talquetamab and teclistamab, can eliminate remaining cancer cells in newly diagnosed multiple myeloma patients who still have detectable disease after initial treatment. About 50 participants will receive talquetamab…

This study tests a telehealth program to help cancer survivors quit smoking, lose weight, and get more active. About 1500 participants will either get coaching sessions or just information. The goal is to see which approach works better for improving long-term health.

This phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other imm…

This study tests whether adding a new oral drug (ivarmacitinib) to standard medicines can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant from a female donor who has given birth. About 82 adults with blood cancers will receive t…

This study tests whether raising blood levels of a natural molecule called beta-hydroxybutyrate (BHB) — through a strict ketogenic diet or ketone drinks — is safe and can improve the effectiveness of immunotherapy (CAR-T cells or bispecific antibodies) in 45 adults with multiple …

This phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…

This study looks at whether providing free bags of groceries to patients undergoing stem cell transplants or CAR-T cell therapy can help improve their nutrition and treatment results. Many patients face high medical costs that make it hard to afford enough food, which can hurt th…

This early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…

This early-stage study tests two drugs—mezigdomide (a pill) and talquetamab (an injection)—in people with multiple myeloma that has come back or stopped responding to prior treatments. The main goal is to find a safe dose and schedule. About 25 participants will receive the drugs…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…

This study tests a new treatment using donor immune cells (CAR-NK cells) that are engineered to recognize and attack cancer. The treatment is personalized based on a tumor's unique markers. It is for adults with advanced solid tumors that have not responded to other therapies. Th…

This early-stage trial is testing NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that have not responded to standard treatments. Participants first receive chemotherapy to prepare their immune system, then an infu…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This study tests whether adding a vitamin A derivative (ATRA) to a standard drug combination (carfilzomib and dexamethasone) can overcome resistance in multiple myeloma patients whose cancer no longer responds to carfilzomib. About 42 adults with relapsed/refractory myeloma will …

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This study tests a treatment called anti BCMA CAR-T cell therapy for adults with multiple myeloma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and kill myeloma cells. The trial aims to see if it is s…

This phase 2 trial is testing whether a combination of four drugs—iberdomide, daratumumab, carfilzomib, and dexamethasone—can shrink or prevent the return of multiple myeloma in patients whose cancer has relapsed or stopped responding to prior treatments. About 30 participants wi…

This early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…

This phase 2 trial is testing whether a radioactive tracer called 18F-fluciclovine can detect multiple myeloma better than the standard FDG tracer during PET/CT scans. The study will enroll 60 adults with newly diagnosed or relapsed/refractory multiple myeloma. Each participant w…

This early-stage study tests a new radioactive tracer called [89Zr]DFO-YS5 for PET scans to find multiple myeloma cells that have a specific protein (CD46). About 20 adults with confirmed multiple myeloma will receive the tracer and have a PET scan. The goal is to see if this met…

Researchers are developing a blood test that uses DNA methylation patterns and machine learning to detect multiple types of cancer at an early stage. The PROFOUND study collects blood samples from people newly diagnosed with cancer and from people without a confirmed cancer diagn…

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

This study tests whether a radioactive tracer called 18F-S16/T807 can help diagnose tau-related brain diseases. Tau is a protein that builds up abnormally in conditions like Alzheimer's and other neurodegenerative disorders. Researchers will give 500 adults a single injection of …

This study is testing a special type of PET/CT scan that looks for a protein called PD-L1 on cancer cells. The goal is to see if this scan can find tumors and their spread more accurately than standard imaging. About 500 adults with suspected or known PD-L1-related cancers will r…

This study tests whether PET/CT scans using two radioactive tracers, 18F-92/AV45 and 11C-PIB, can detect beta amyloid buildup in the brain. Researchers will enroll 500 adults with suspected or known neurodegenerative diseases linked to amyloid. Each participant receives one injec…

This trial tests whether an injected tracer called HED, seen on PET/CT or MRI scans, can help diagnose diseases of the sympathetic nervous system, the part of the body that controls automatic responses like heart rate and blood pressure. Researchers will scan 500 adults who have …

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This study compares a blood test (liquid biopsy) to the standard tissue biopsy for finding genetic changes in advanced solid tumors. The goal is to see if the liquid biopsy can accurately detect the same genetic alterations as the tissue sample. If it works, patients might avoid …

This study collects blood samples from healthy people, those with benign diseases, and cancer patients to develop a multi-analyte blood test. The test looks for DNA methylation markers that may indicate the presence of various cancers, especially liver cancer. Researchers aim to …

This study tests whether a special CT scan with contrast dye can give clearer images of tumors during radiation therapy. Twenty adults with advanced cancer will receive the extra scan alongside their standard treatment. The goal is to see if this approach is feasible and improves…

This study is testing a new radioactive imaging agent called 68Ga-DOTA-EphA2 to help see certain proteins on cancer cells during PET/CT scans. The goal is to improve how doctors detect and monitor malignant tumors. About 30 adults with suspected or confirmed cancer will receive t…

This study tests an improved whole-body MRI that uses special 'pseudo-CT' sequences to detect bone lesions in people with multiple myeloma. The goal is to see if this single, radiation-free scan can accurately find bone damage. About 45 patients with newly diagnosed or recurrent …

This study tests whether taking a daily statin (rosuvastatin) for one year can safely prevent life-threatening blood clots in people with cancer. Current clot-preventing drugs raise bleeding risks, so a safer option is needed. The trial will enroll 4,000 adults with newly diagnos…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …

This phase 3 trial is testing whether adding Gamunex-C (an immune globulin) to standard care can prevent serious infections in people with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma. About 49 participants will receive Gamunex-C through an IV every 4 w…

This study tests whether cooling and compressing the arms and legs during taxane chemotherapy can prevent peripheral neuropathy—a common side effect causing numbness, tingling, or pain. About 777 cancer patients will be randomly assigned to one of three approaches: cryocompressio…

This study tests whether different types of massage can lower anxiety in cancer patients while they receive chemotherapy. Fifty adults who already have high anxiety and are at least one cycle into chemo will receive massage during their infusion sessions. Researchers will measure…

This study is testing whether a virtual, 8-session group therapy program can help cancer patients find meaning and reduce emotional distress. Researchers at MD Anderson Cancer Center will enroll 72 adults with a history of cancer. Participants will attend weekly 90-minute session…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…

Chemotherapy often causes nausea and vomiting, which is especially hard for children. This study tests a new IV drug called NEPA (fosnetupitant/palonosetron) to prevent these side effects in kids with cancer. The trial has two parts: first, an open-label phase to find the right d…

This study tests whether an artificial intelligence (AI) app can improve quality of life, anxiety, and depression in people with cancer who are already receiving psychotherapy. About 60 participants will be randomly assigned to either get the AI app alongside their usual therapy …

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This pilot study tests a 4-week personalized exercise program for people aged 70 and older who are about to have cancer surgery. Participants follow daily exercises at home using a smartphone app. The goal is to see if this approach improves their physical fitness before the oper…

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…

This pilot study is testing a combined program of mobile health exercise and cognitive rehabilitation for older cancer survivors (age 60+) who have concerns about memory or thinking after treatment. The program uses a smartphone app for exercise tracking and group workshops for b…

This study tests whether using a virtual reality helmet during painful medical procedures (like needle sticks or bone marrow tests) can reduce pain in children with cancer. About 74 children aged 6 to 18 will be split into two groups: one gets standard care plus the VR helmet, th…

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…

This study tests a 4-month coaching program called SONATA that helps older adults (age 60+) with advanced cancer build a support network of family and friends. The goal is to see if this social support makes it easier to stick with treatment and feel better. About 330 patients an…

This study tests whether a walking program and cognitive rehabilitation exercises can improve memory and thinking in people aged 65 and older who have finished cancer treatment. Forty participants will be randomly assigned to one of four groups: exercise only, cognitive training …

This study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…

This study tests an online, therapist-guided program to help cancer survivors who have anxiety, depression, or fear of cancer returning. About 400 adults in Sweden who finished cancer treatment at least 6 months ago will take part. The goal is to see which parts of the 10-week on…

This trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…

This study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…

This trial tests whether a dedicated 'return-to-work after cancer' consultation can help people who have been treated for blood cancers like leukemia, lymphoma, or multiple myeloma get back to their jobs. The consultation, led by an occupational health specialist with possible su…

This study looks at whether a computer-assisted vacuum procedure to remove blood clots from the lungs is safe and improves quality of life for cancer patients with a moderate-risk pulmonary embolism. About 25 adults with cancer and a confirmed clot in a major lung artery will tak…

This study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…

This study tests whether a short psychotherapy called brief behavioral activation (BBA) can reduce depression and anxiety and improve well-being in older adults who have survived cancer. BBA encourages people to set goals and engage in enjoyable or rewarding activities to change …

This pilot study will give 20 early-stage cancer patients a preloaded cash card with $1,000 each month. The goal is to see if this simple cash support can prevent financial hardship, like debt or missed rent, and improve treatment outcomes. Researchers will measure how many peopl…

This study tests whether a single early meeting with a psycho-oncology counselor can reduce anxiety and depression and improve quality of life in people recently diagnosed with cancer. About 148 patients will be randomly assigned to either receive this counseling plus standard ca…

This study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…

This study tests whether a tailored coaching program can help adolescents and young adults (ages 15-24) with cancer take their oral medications as prescribed. Participants will work with a coach over four sessions to identify and overcome barriers to adherence, using an electroni…

This study tests whether a virtual exercise program with peer support helps older adults (60+) with cancer become more active and feel better. Participants are matched with a peer and receive guidance from exercise professionals or just peer support, compared to usual care. Over …

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

This study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…

This trial tests an AI-based platform called Gustabor that creates personalized meal plans for cancer patients experiencing taste disorders from chemotherapy. The study includes adults with multiple myeloma or gastrointestinal cancer who have taste changes and mainly eat by mouth…

This study tests whether an AI-based website that gives personalized diet tips and recipes can help cancer patients who experience taste changes during therapy. About 198 adults with certain cancers (like multiple myeloma, melanoma, or GI cancers) will either get the AI tool or a…

This study tests whether a tailored physical activity program can help older adults maintain thinking and memory after a stem cell transplant for blood cancers. Participants aged 60 and older will follow a progressive, light-to-moderate exercise plan with support from therapists …

This trial tests a program called ACT, which trains doctors and nurses to have compassionate, structured conversations with blood cancer patients and their families about end-of-life care. The goal is to help patients understand their prognosis and make informed decisions, potent…

This trial tests whether a specially designed website, called Mosaic, can help blood cancer patients who are about to undergo a stem cell transplant feel less distressed and have a better quality of life. Participants are randomly assigned to use either the Mosaic website or a st…

This trial tests whether two types of home-based digital cognitive training can help cancer survivors who have memory, attention, or thinking problems after chemotherapy. Participants will use either a computer program (BrainHQ) or a virtual reality cognitive training for 10 week…

This phase II trial tests whether a plant-derived supplement called chlorophyllin can reduce severe mouth sores caused by high-dose radiation given before a stem cell transplant. People aged 12 to 65 with blood cancers who need total body irradiation as part of their transplant p…

This pilot study tests a hybrid intervention that combines a digital platform (Findhelp.org) with human navigation sessions to help adolescent and young adult cancer survivors manage financial and health-related social needs. Researchers will refine the approach with input from s…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

This trial tests whether a small pump implanted in the abdomen that delivers pain medicine directly to the spinal fluid can improve quality of life for people with severe cancer pain that is not controlled by oral opioids. Participants are randomly assigned to get the pump or to …

This study tests whether a combined lifestyle program—focusing on nutrition, physical activity, sleep, stress, and sense of purpose—can improve quality of life for people with cancer. It includes cancer survivors within five years of curative treatment and those with advanced can…

This study looks at whether using a weighted blanket during intravenous cancer treatment can help lower anxiety, stress, and depression, and improve comfort. About 152 adults with solid cancers who are starting their first IV therapy will be randomly assigned to receive either a …

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study looks at whether a custom website can improve quality of life for people with multiple myeloma. About 108 adults with newly diagnosed or returning myeloma will use the platform to report side effects and get personalized tips. The goal is to see if this digital support…

This study tests an online program called My Wellbeing Guide for cancer patients who feel depressed or anxious. The program uses videos, activities, and written tips based on cognitive behavioral therapy over 7 weeks. About 6,500 participants will be randomly assigned to the prog…

This study tests a program called TRACT that helps cancer patients with travel to their radiation therapy appointments. Many patients miss or delay treatment due to transportation issues. The program provides navigation support and resources. Researchers will see if it is practic…

This study tests whether a combination of diosmin and hesperidin, natural compounds found in citrus fruits, can protect the kidneys of cancer patients receiving platinum-based chemotherapy. One hundred adults with confirmed cancer will take the supplement alongside their chemo to…

This study tests whether a 12-week personalized exercise program, done at home with a trainer guiding via video, can improve quality of life and reduce common side effects like fatigue, anxiety, and nerve pain in cancer survivors. About 350 adults who finished cancer treatment wi…

This study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…

This study looks at whether a diet that includes longer overnight fasting and follows a Mediterranean eating pattern is practical for people with multiple myeloma or its early forms (MGUS or smoldering myeloma). About 120 adults will try this approach to see if they can stick wit…

This study tests whether an internet-based parent-child interaction therapy (I-PCIT) can help improve behavior in children aged 2-12 who have or had cancer. Parents of 300 children will be randomly assigned to start therapy right away or wait 5-6 months. The goal is to see if the…

This study tests a program called ENABLE-SG, which provides phone-based coaching sessions to people recently diagnosed with advanced cancer and their caregivers. The goal is to help them manage stress, symptoms, and planning early on, rather than waiting for a crisis. Researchers…

This study tests a program where cancer patients report symptoms from home using a digital questionnaire. A nurse monitors the results and provides advice between clinic visits. The goal is to see if this improves quality of life and reduces emergency room visits and hospital sta…

This study tests a program called Sentinel that trains stem cell transplant doctors to provide palliative care—like managing symptoms and coping strategies—as part of routine care. The goal is to see if it's feasible and acceptable for patients. Forty adults undergoing stem cell …

This study looks at whether a one-day hospital visit that includes medical, psychological, and social support can help teens and young adults (ages 15-25) feel better after finishing cancer treatment. About 214 participants who have completed treatment for a solid tumor or lympho…

This study is testing whether a 6-month, personalized exercise program can improve the quality of life for people with multiple myeloma. The program mixes in-person sessions at the hospital with at-home workouts. Researchers will compare participants who get the exercise program …

This study tests whether a special palliative care program (called PEACE) can improve quality of life for people with blood cancers like lymphoma, leukemia, or multiple myeloma who are receiving adoptive cellular therapy (ACT). About 90 participants will be randomly assigned to e…

This study looks at whether medical hypnosis can help reduce anxiety in people with solid tumors who are getting radiation therapy. About 45 moderately to very anxious patients will either listen to relaxing music alone or combine it with hypnosis during their sessions. The goal …

This study tests whether a computer brain-training program (Lumosity) can improve memory and thinking in adults who had a stem cell transplant for blood cancer. About 60 survivors, 3 to 6 months after transplant, will either start training right away or wait 12 weeks. The goal is…

This study tests whether immersive virtual reality (VR) exercises can improve memory, attention, and thinking speed in people with cancer who have mental fogginess after chemotherapy. Sixty participants will either use VR-based cognitive, physical, and mindfulness training or do …

This study tests whether a single 25 mg dose of psilocybin can relieve major depression in 100 adults with cancer, compared to a very low 1 mg dose. Participants must be 20–80 years old, have had depression for at least a month after their cancer diagnosis, and stop other antidep…

This study tests whether a smartphone app called Resilience PRO can improve quality of life for cancer patients receiving chemotherapy or other systemic treatments. About 1,458 adults with any stage of cancer will either use the app to report symptoms (with alerts sent to their c…

This study tests a mobile app called THRIVE-CAR-T designed to support patients during CAR-T cell therapy. Researchers want to see if the app is easy to use and acceptable to patients. About 100 adults with blood cancer receiving CAR-T treatment will participate. The app provides …

This study tests whether specially trained nurses can help children with cancer and their families by starting conversations about palliative care early. About 120 children recently diagnosed with cancer will be randomly assigned to either receive these nurse-led talks or standar…

This study tests whether a structured, symptom-driven care pathway improves symptom control and satisfaction for adults with advanced cancer receiving outpatient palliative care. 120 participants will be randomly assigned to either standard care or a tailored pathway that trigger…

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study interviews cancer care providers, patients, and caregivers to learn their thoughts and feelings about receiving hospital-level care at home. The goal is to understand what people know and believe about home hospital care, so that future programs can be designed to bett…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study tests whether a video and personal guidance can help Black, Latinx, and older adults with cancer get genetic testing. Genetic testing is often needed to join precision cancer trials. The goal is to make trial enrollment more equitable. About 210 people with gastrointes…

Researchers at Peking University First Hospital are building a prospective cohort of 2,000 people with plasma cell disorders, including multiple myeloma, amyloidosis, and related conditions. Participants give blood, bone marrow, and urine samples before and after treatment, and t…

This study is building an AI tool called ACTIVATE that scans electronic health records to find cancer patients who may be eligible for clinical trials. Researchers will test whether sending alerts to doctors increases the number of patients starting trials. The goal is to make it…

This study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …

This study tests a communication tool called TrialTalk™ in cancer clinics. The goal is to see if it helps doctors and patients talk more clearly about treatment options. About 30 patients and their doctors will fill out questionnaires before and after a regular visit. The study f…

This study is testing an educational program designed to help racial and ethnic minority cancer patients make informed decisions about joining clinical trials. The program involves watching short videos and talking with a patient navigator. Researchers will measure changes in pat…

This study aims to understand why multiple myeloma affects African American, Latino, Asian American, and White patients differently. Researchers will survey 4000 people diagnosed with multiple myeloma in California to learn about factors that may influence who gets the disease an…

This study tests whether a telementoring program called ECHO can improve the quality of palliative care for advanced cancer patients in underserved areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia. Researchers will train local doctors through online clinics and w…

This study tests a program called SUPPORT that helps Black and Latino cancer patients learn about and join clinical trials. The program includes a website and a navigator who guides patients. Researchers will see if this increases the number of patients referred to and enrolled i…

Some cancer drugs cause rare but serious heart and metabolic problems. This study follows 5,000 cancer patients across several French hospitals who receive a dedicated heart checkup and ongoing follow-up through cardio-oncology programs. Researchers track how many patients benefi…

This study tests a telehealth program that helps older adults (60+) with blood cancers like leukemia or MDS talk to their doctors about their care wishes. The program also helps them fill out advance directive forms. Researchers want to see if it improves communication and reduce…

This study uses online surveys to explore whether cancer patients and their family members across the European Union have equal access to mental health screening and psychological support. Researchers will analyze responses from 2,000 participants to identify disparities, barrier…

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

This study looks at how platinum-based chemotherapy can cause permanent hearing loss in cancer patients, and whether people from poorer backgrounds are more affected. Researchers will test hearing and thinking skills in 172 patients from North West England before and after treatm…

This observational study builds a national registry of people with multiple myeloma in Italy. Researchers collect information from routine care at different hematology centers to describe how patients are diagnosed and treated. The registry tracks overall survival, time to next t…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …

This study looks at whether men and women experience different side effects from cancer immunotherapy. Researchers will track symptoms and quality of life in 100 adults starting standard immunotherapy. The goal is to better understand how sex and gender influence treatment experi…

This study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…

This study follows 700 cancer patients who take blood thinners and are scheduled for surgery or medical procedures. Researchers will track how often major bleeding or clotting events occur within 30 days after the procedure. The goal is to see if current blood thinner management …

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…

This study looks at whether offering money for things like travel, lodging, and childcare helps more people from different backgrounds join cancer clinical trials. Researchers will track enrollment and retention of 1,200 patients who are already in a cancer trial. They will compa…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …

This study provides ongoing check-ups for people who received a donor stem cell transplant at the NIH at least three years ago. Researchers will monitor for late side effects, disease return, and overall health. Participants will have yearly visits that may include blood tests, b…

This study tests whether tracking changes in infection markers and blood culture results over time can help detect sepsis earlier and monitor treatment in adults with cancer. Researchers will follow 100 patients with suspected sepsis during their hospital stay and for up to 30 da…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study tests a program that screens cancer patients for emotional distress and refers them to mental health services if needed. It involves 50 English- or Spanish-speaking adults with new solid tumor cancers at Jamaica Hospital Medical Center. The goal is to see if such a pro…

This study looks at whether exercise after finishing cancer treatment is linked to better outcomes, like longer survival without the cancer coming back. Researchers will analyze data from 1,000 adult cancer survivors at Memorial Sloan Kettering. The goal is to see if those who ex…

This study looks at whether giving fiber supplements to patients undergoing donor stem cell transplants is practical and well-tolerated. The goal is to see if fiber can support nutrition and gut health after the harsh effects of chemotherapy and radiation. The trial will enroll 4…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This trial tests whether 3D-printed molds, created from radiological images, can guide pathologists to sample the most informative parts of a removed tumor. Currently, sampling is done by eye, which may miss key regions. The study will compare samples taken with the mold to stand…

This study looks back at the experiences of 60 adults with relapsed or refractory multiple myeloma who received a stem cell transplant from a donor. The goal is to measure how long patients live without their cancer progressing after this procedure. By gathering real-world data, …

This study is testing whether wearable activity trackers like Fitbits and iPhones can help predict when cancer patients undergoing radiation therapy might need emergency care or hospitalization. Researchers will collect step counts and other health data from 260 participants to b…

This study is a large registry that tracks cancer patients who receive both radiotherapy and molecular therapies, such as immunotherapy. The goal is to better understand how these two treatments interact and to identify how often severe side effects occur. By collecting data from…

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This study enrolls people diagnosed with cancer to build a large registry using Olivia, an AI-powered health platform. The platform will collect and combine electronic health records and patient-reported outcomes from over 1,000 healthcare systems. The goal is to create a compreh…

This study tests whether a routine digital screening followed by a supportive phone call can help cancer survivors get the emotional and social support they need after finishing primary treatment. Fifty adults who have completed cancer therapy will take part. The goal is to see i…

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This observational study tracks 7,000 men and women with cancer to see how treatments like chemotherapy, radiation, and immunotherapy affect fertility. In women, researchers measure a hormone called AMH to gauge ovarian reserve; in men, they analyze sperm quality. The goal is to …

This study tests whether a survivorship care plan is practical for blood cancer patients who have had a stem cell transplant. Researchers will track how many patients stick with the program and measure their quality of life, unmet needs, and caregiver burden. The goal is to see i…

This study follows 400 people in Norway with multiple myeloma, plasma cell leukemia, or AL amyloidosis who are receiving newer immunotherapies like teclistamab, elranatamab, or CAR-T cell therapy outside of clinical trials. Researchers will track how well these treatments control…

This study aims to make clinical trials more inclusive by training 40 adults who are in remission from blood cancer to review and give feedback on trial plans. The goal is to see if this community-based review process is practical and acceptable. The study does not test a new tre…

This study will test a new robotic surgery platform called RonovoTM in 40 adults with cancer who need elective surgery. The robot helps surgeons perform minimally invasive procedures in digestive, thoracic, urology, and gynecology areas. Researchers will track complications, tech…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study investigates whether the health of a patient's immune cells can predict how well they will respond to CAR-T or bispecific antibody treatments for relapsed multiple myeloma. Researchers will analyze blood samples from patients aged 65 and older before they start standar…

This observational study will survey 1,000 cancer patients about their use of dietary supplements like vitamins, minerals, and herbal products. Researchers want to know how common supplement use is, whether patients experience side effects, and if these supplements could interact…

This study is translating and testing an Italian version of a questionnaire that measures anxiety in cancer patients during whole-body MRI scans. Researchers will enroll 175 adult cancer patients at the European Institute of Oncology. The goal is to ensure the Italian version is …

SPECTA is a large research platform that collects tumor samples, genetic data, and patient information from nearly 5,000 people with all types of cancer. The goal is to help scientists better understand cancer biology and find new ways to match patients with the right clinical tr…

This study is collecting data from 2,000 adults with solid tumors who undergo theranostic PET scans as part of their routine care. The goal is to see how well these scans detect tumors and match with lab results, which could help doctors make better treatment decisions. Participa…

This study follows 500 adults in the Languedoc-Roussillon region of France who have or are suspected of having a blood cancer (hematologic malignancy). Researchers will collect medical records, blood samples, and quality-of-life questionnaires to track survival at 2, 5, and 10 ye…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…

This study looks at liver inflammation (hepatitis) that can occur in cancer patients treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers aim to describe the different patterns of liver injury and how they respond to treatment. By collecting real-world …

This study is collecting blood and urine samples from 150 cancer patients who have had blood clots. The goal is to learn more about why clots happen in cancer and how to prevent them. Participants will be followed over time to track clot recurrence and bleeding risks.

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study investigates whether changes in the GBA and PSAP genes are more common in people with multiple myeloma or its precursor condition, MGUS. Researchers will compare the frequency of these gene variants in 300 patients against known population databases. The goal is to bet…

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study aims to build a large biobank of blood samples from 40,000 cancer patients to help identify biomarkers that can predict survival and response to treatment. Participants provide an extra 36ml of blood during routine blood draws. The samples will be used in future resear…

This study collects blood and tumor samples from 700 adults receiving approved CAR-T therapy for blood cancers. Researchers will analyze these samples to identify biological markers that predict whether the therapy will work or if the cancer will return. The goal is to improve fu…

This study is testing whether genetic testing of tumors and blood can help doctors choose better treatments for people with rare cancers. About 400 adults with rare solid tumors or lymphomas will have their tumors genetically analyzed. A team of experts will review the results an…

This study follows 270 young women treated for lymphoma with chemotherapy to see how their ovaries recover over 5 to 10 years. Researchers measure hormone levels and egg counts to understand long-term fertility and pregnancy rates. The goal is to help doctors give better advice o…

This study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…

This study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…

This study follows 1,538 cancer patients in China to see how their nutritional status affects how well they handle chemotherapy and radiation, their quality of life, and how long they live. Researchers will track changes in diet, weight, and blood markers over time. The goal is t…

This study is a worldwide registry that follows 5,000 adults with breast cancer, blood cancers, or those on immune checkpoint inhibitors. Researchers collect medical records, lab results, and imaging to identify who is at risk for heart problems during or after cancer treatment. …

This study is building a registry of 500 children, teens, and young adults (ages 1-39) diagnosed with cancer. Participants will complete physical and mental function tests, surveys, and provide blood samples over time. The goal is to learn how cancer and its treatments affect agi…

This study is for people with advanced cancers who are taking long-term targeted treatments. Researchers want to learn about their experiences through interviews. The goal is to find better ways to support these patients. The study is currently recruiting 75 participants.

This study looks at whether giving doctors genetic information about their patients can help them choose safer and more effective pain medications. Researchers will enroll 800 cancer patients who are expected to need opioid painkillers. Half will have their genes tested to guide …

This study is collecting blood samples from 300 cancer patients to look for immune cells that target tumors. Researchers want to understand how the immune system responds to cancer and treatments. The study does not test a new drug or therapy, but aims to gather knowledge that co…

This study tests a program called ALIGN, which uses palliative care social workers and patient navigators to support older adults with advanced cancer who are moving from the hospital to a skilled nursing facility. The goal is to see if the program is practical and can help align…

This study looks at how satisfied cancer patients are after a special team assessment in a day hospital. About 309 adults with cancer will fill out a questionnaire after meeting with a pharmacist, dietitian, psychologist, social worker, and other care providers. The goal is to fi…

This study follows 2000 people with multiple myeloma in the West-Occitanie region of France to see how they are treated in real life and how their quality of life changes over time. Researchers will collect data from medical records and ask patients to fill out questionnaires abo…

This study is testing a new genetic test called the MyeloGen Gene Panel to see if it can quickly and reliably find inherited risks for myeloid cancers (a type of blood cancer). Researchers will take a small skin sample from 200 adults with these cancers and analyze it for genetic…

This study uses online surveys to learn about the real-life experiences of people diagnosed with cancer and their caregivers. Researchers want to understand the emotional, physical, social, and financial challenges they face. The goal is to use this information to improve support…

This study looks at whether it is safe and beneficial for people with advanced cancer to stop taking statins, which are cholesterol-lowering drugs often used for prevention. Researchers will follow 80 patients in palliative care for 12 weeks, monitoring cholesterol levels, muscle…

This study collects and analyzes personal writings from 500 teenage cancer patients to understand their emotions and experiences. The goal is to improve communication between patients and healthcare providers and make hospital care more supportive. No new drugs or treatments are …

This study is creating a network of hospitals in Italy to find and treat AL amyloidosis earlier. Researchers will screen people with certain blood conditions (MGUS or smoldering myeloma) using special tests. The goal is to speed up diagnosis, connect patients to the right care, a…

This study tests whether using artificial intelligence (AI) to rewrite medical discharge letters into plain language helps cancer patients better understand their diagnosis, treatment, and next steps. About 150 adults with blood cancer or other cancers will be randomly assigned t…

This study tests whether special heart MRI scans can find early signs of heart damage in cancer patients getting anthracycline chemotherapy. Current tests often miss this damage until it's advanced. About 93 adults will get several MRI scans before, during, and after treatment. T…

This study aims to validate a questionnaire that measures anxiety in cancer patients before surgery. Researchers will test the Italian version of the Surgical Anxiety Questionnaire (SAQ) with 180 adult patients. The goal is to better understand patients' fears and concerns so tha…

This study is for 1,000 adults with early blood conditions called MGUS or smoldering multiple myeloma. Researchers want to find out why some people's conditions stay stable while others progress to active multiple myeloma. Participants will provide samples and have regular check-…

This study follows children and teens who had radiation to the brain before age 16 to check for hormone problems. Researchers will measure hormone levels and track fatigue to create better follow-up guidelines. About 230 participants in remission from cancer will be monitored for…

This study is for 80 adults with blood cancers like MDS or AML who are starting treatment. Participants wear a smartwatch and answer questionnaires to track their activity, symptoms, and quality of life. The goal is to help doctors better understand when patients need blood trans…

This study is testing whether wearable devices that monitor heart rate and other vital signs can help doctors and nurses spot infections and other problems earlier in hospice patients with advanced cancer. The researchers will also see if these measurements can help predict how l…

This study looks at people who developed cancer at a young age (before 40, or before 30 for breast cancer) but had normal results on standard genetic tests. Researchers will use a more advanced technique called exome sequencing to search for new genetic changes that might raise c…

This study looks at how SPECT imaging can help doctors measure the amount of radiation reaching healthy organs during certain cancer treatments. About 80 adults with advanced prostate or other cancers will get extra SPECT scans before and after their standard radiation therapy. T…

This study is testing a short set of questions to see if it can consistently capture the support needs and symptoms of cancer patients. Researchers will ask 900 patients and their healthcare providers about how easy and useful the questions are. The goal is to create a standard t…

This study is collecting information from up to 10,000 cancer patients to see if choosing treatments based on the genetic makeup of their tumors leads to better outcomes. Researchers will look at medical records and may test leftover tissue or blood samples to create a genetic pr…

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…

This study will analyze the genes of 25,000 adults who have cancer or are at risk for it. Researchers will use advanced testing to find genetic changes linked to cancer and track health records over time. The goal is to learn more about cancer biology and discover new ways to per…

This study tests a communication program called COACH-Cog for older adults with both dementia and cancer. It includes a training video for doctors and a coaching session for patients and their care partners. The goal is to see if this helps everyone work together better when maki…

This study is creating a database of up to 5,000 people in Ohio with plasma cell disorders like multiple myeloma and amyloidosis. Researchers will track treatments, outcomes, and quality of life, while also offering patients access to expert consultations and information about su…

This registry study is collecting data from 2,800 cancer patients treated with ion beam therapy (protons and carbon ions) at MedAustron. Researchers will track tumor response, survival, side effects, and quality of life over time. The goal is to better understand the real-world b…

This study is collecting genetic and health information from 120,000 people aged 65 and older who have a personal or family history of cancer. The goal is to see if genetic testing can help doctors find cancer risks earlier and guide prevention efforts. Participants will provide …

This study tests a personalized approach for patients with advanced liver or colorectal cancers that no longer respond to standard treatments. Doctors take a small sample of the tumor, grow it in the lab as 3D 'organoids', and test different drugs on them to see which works best.…